肺表面活性物质(pulmonary surfactant,PS)替代疗法可明显降低呼吸窘迫综合征(respiratory distresssyndrome,RDS)病死率及气胸发生率,同时可改善肺顺应性和通换气功能,降低呼吸机参数,肺表面活性物质目前已常规用于预防或治疗RDS,在临床上已广泛推广,但其价格昂贵,选择一种成功的给药方法是必须的。气管导管内推注注射用牛 Surfactant replacement therapy with pulmonary surfactant (PS) can significantly reduce mortality and pneumothorax incidence in patients with respiratory distress syndrome (RDS), improve lung compliance and ventilatory function, and decrease ventilatory parameters, lung Surfactants are currently routinely used for the prevention or treatment of RDS and have been widely used clinically, but they are expensive and it is necessary to choose a successful delivery method. Intubation Catheter injection of cattle